Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

RegulatoryapprovedAdvanceAD-Tx™Positive

AI Analysis

Summary

Castle Biosciences announced New York State Department of Health approval of its AdvanceAD-Tx™ diagnostic test designed to guide systemic treatment decisions in patients with moderate-to-severe atopic dermatitis, expanding access to the precision medicine test.

Outcome Details

New York State Department of Health approval of AdvanceAD-Tx™ test for systemic treatment decision making in moderate-to-severe atopic dermatitis

Importance:5/10

Sentiment:

0.70

regulatory_approvalprecision_medicinedermatologydiagnostic_teststate_approval

Related Companies

$CSTL

Read the original article

Published by PR Newswire Pharma on July 14, 2026 8:30 PM

Read Original